KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Common Equity: 2009-2025

Historic Common Equity for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $503.9 million.

  • Halozyme Therapeutics' Common Equity rose 11.31% to $503.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $503.9 million, marking a year-over-year increase of 11.31%. This contributed to the annual value of $363.8 million for FY2024, which is 334.11% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Common Equity is $503.9 million, which was up 51.44% from $332.7 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Common Equity peaked at $503.9 million during Q3 2025, and registered a low of $65.8 million during Q1 2023.
  • For the 3-year period, Halozyme Therapeutics' Common Equity averaged around $286.6 million, with its median value being $289.4 million (2024).
  • Its Common Equity has fluctuated over the past 5 years, first slumped by 74.70% in 2023, then skyrocketed by 334.11% in 2024.
  • Over the past 5 years, Halozyme Therapeutics' Common Equity (Quarterly) stood at $197.0 million in 2021, then dropped by 13.79% to $169.8 million in 2022, then tumbled by 50.64% to $83.8 million in 2023, then soared by 334.11% to $363.8 million in 2024, then rose by 11.31% to $503.9 million in 2025.
  • Its last three reported values are $503.9 million in Q3 2025, $332.7 million for Q2 2025, and $482.3 million during Q1 2025.